Company Encyclopedia
View More
name
NKF
603707.SH
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, haloperidol decanoate, busulfan, gemcitabine hydrochloride, dexmedetomidine hydrochloride, nelarabine, rocuronium bromide, zoledronic acid, bupivacaine hydrochloride, plerixafor, eptifibatide, fondaparinux sodium, docetaxel, fluorouracil, palonosetron hydrochloride, oxaliplatin, fulvestrant, and adalimumab injections. The company offers bortezomib, bendamustine hydrochloride, mycophenolate mofetil, vancomycin hydrochloride, daptomycin, decitabine, voriconazole, tigecycline, melphalan hydrochloride, actinomycin, micafungin, azacitidine, pantoprazole sodium, mitomycin, pemetrexed disodium, thiotepa, and dacarbazine for injections.
3.159 T
603707.SHMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking96/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.98%B
    • Profit Margin17.28%A
    • Gross Margin38.42%B
  • Growth ScoreC
    • Revenue YoY-3.00%D
    • Net Profit YoY253.64%A
    • Total Assets YoY9.34%B
    • Net Assets YoY7.73%B
  • Cash ScoreC
    • Cash Flow Margin578.82%C
    • OCF YoY-3.00%D
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreB
    • Gearing Ratio34.50%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NKF released its performance for the first three quarters, with a net profit attributable to the parent company of 429 million yuan, a year-on-year decrease of 29.11%

    According to the Zhitong Finance APP, NKF disclosed its third-quarter report for 2025. The company achieved a revenue of 2.926 billion yuan in the first three quarters, a year-on-year decrease of 5.25%; the net profit attributable to the parent company was 429 million yuan, a year-on-year decrease of 29.11%; the net profit excluding non-recurring gains and losses was 384 million yuan, a year-on-year decrease of 29.95%; the basic earnings per share were 0.27 yuan

    Zhitong·
    SH
    603707
    -0.21%
    Zhitong·
    SH
    603707
    -0.21%

    NKF: Subsidiary Meitheal Pharmaceuticals Inc. received new drug injection registration approval from the U.S. FDA for phosphomycin

    NKF announced that its subsidiary Meitheal Pharmaceuticals Inc. has received an approval letter from the U.S. Food and Drug Administration for the new drug injectable fosfomycin, 6g/bottle. The company has invested approximately 47.211 million yuan in research and development expenses. The newly approved product will be arranged for sale in the United States in the near future, which is expected to have a positive impact on the company's operating performance

    Zhitong·
    SH
    603707
    -0.21%
    Zhitong·
    SH
    603707
    -0.21%

    NKF: Products exported to the U.S. are generic drugs, and the impact of tariffs needs further observation

    On September 25th, local time, U.S. President Trump announced on his social media platform "Truth Social" that starting October 1st, the U.S. will impose a 100% tariff on patented and branded drugs. In response, the securities department of NKF told reporters who called as investors, "As of now, it should cover patented and original research drugs. We mainly deal in generic drugs, and we currently do not see any impact on us; we will need to further observe the official interpretation."

    Zhitong·
    SH
    603707
    -0.21%
    Zhitong·
    SH
    603707
    -0.21%

    NKF released its semi-annual performance report, with a net profit attributable to the parent company of 286 million yuan, a year-on-year decrease of 29.32%

    According to the Zhitong Finance APP, NKF disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.98 billion yuan, a year-on-year decrease of 7.60%; net profit attributable to the parent company was 286 million yuan, a year-on-year decrease of 29.32%; net profit excluding non-recurring gains and losses was 260 million yuan, a year-on-year decrease of 29.46%; basic earnings per share were 0.18 yuan

    Zhitong·
    SH
    603707
    -0.21%
    Zhitong·
    SH
    603707
    -0.21%

    NKF's subsidiary has obtained the US FDA's registration approval for the transfer of the production site of Etoposide Injection

    NKF's subsidiary Meitheal Pharmaceuticals, Inc. recently received approval from the U.S. FDA, allowing Jianjin Pharmaceutical Co., Ltd. to produce Etoposide Injection (100 mg/5 mL, 500 mg/25 mL, and 1 g/50 mL). The new product will be launched in the U.S. soon and is expected to have a positive impact on the company's performance

    Zhitong·
    SH
    603707
    -0.21%
    Zhitong·
    SH
    603707
    -0.21%
    © 2025 Longbridge｜Disclaimer